Eradication of Malignant Carcinoma in the Breast Tissue

Optimal Health Research

Status and phase: Completed; Phase 3; Phase 2

Conditions: Breast Cancer

Treatments: Dietary Supplement: Acetogenins; Dietary Supplement: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT02286778

F-9892131B

Details and patient eligibility

About

The purpose of this study is to confirm the findings of an early study and expand our knowledge of treating Malignant Carcinoma in the Breast Tissue Using an ATP (Adenosine-5'-Triphosphate) Inhibitor.

Enrollment: 60 patients

Sex: Female

Ages: 35 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of breast cancer
• Referred to the study by their treating physician

Exclusion criteria

• Any type of treatment for breast cancer before starting the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

60 participants in 3 patient groups, including a placebo group

Acetogenins

Active Comparator group

Description:

Dietary Supplement: Acetogenins BID for 12 months

Treatment:

Dietary Supplement: Acetogenins

Placebo

Placebo Comparator group

Description:

Dietary Supplement: No Acetogenins BID for 12 months

Treatment:

Dietary Supplement: Placebo

Control

No Intervention group

Description:

Control subjects will not receive the Acetogenins or the placebo. They will be evaluated every other month to monitor disease progress.